The 130-year old healthcare conglomerate sells everything from baby shampoo to surgical staples and cancer drugs (it also divested itself of Splenda, the artificial sweetener.) That diversification helped buoy giant J&J in 2015; the company’s strong pharmaceutical sales made up for the less impressive performances of its consumer and medical device divisions. The company’s revenues grew 2.6% in the US, but slid 5.7% worldwide in 2015, largely due to currency fluctuations and the sharp decline in sales of its Hepatitis C drug, Olysio.
News about Johnson & Johnson
Don't rewrite your business model just yet.
Biosimilars in the U.S. aren't as cheap as some had hoped.
Despite threats to its blockbuster Remicade drug
Teenage aspiring STEM leaders sat down one-on-one with some of the world's biggest execs.
The bank should have looked to Johnson & Johnson and GM for inspiration.
Videos about Johnson & Johnson
According to this Johnson & Johnson exec